- Home
- WRLD vs CGEM Comparison
WRLD vs CGEM Comparison
Compare WRLD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- CGEM
- Stock Information
- Founded
- WRLD 1962
- CGEM 2016
- Country
- WRLD United States
- CGEM United States
- Employees
- WRLD N/A
- CGEM N/A
- Industry
- WRLD Finance: Consumer Services
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- WRLD Finance
- CGEM Health Care
- Exchange
- WRLD Nasdaq
- CGEM Nasdaq
- Market Cap
- WRLD 656.7M
- CGEM 730.2M
- IPO Year
- WRLD 1991
- CGEM 2021
- Fundamental
- Price
- WRLD $141.16
- CGEM $9.03
- Analyst Decision
- WRLD
- CGEM Strong Buy
- Analyst Count
- WRLD 0
- CGEM 7
- Target Price
- WRLD N/A
- CGEM $32.50
- AVG Volume (30 Days)
- WRLD 29.6K
- CGEM 432.6K
- Earning Date
- WRLD 01-28-2025
- CGEM 03-13-2025
- Dividend Yield
- WRLD N/A
- CGEM N/A
- EPS Growth
- WRLD 29.62
- CGEM N/A
- EPS
- WRLD 14.42
- CGEM N/A
- Revenue
- WRLD $558,622,726.00
- CGEM N/A
- Revenue This Year
- WRLD N/A
- CGEM N/A
- Revenue Next Year
- WRLD $3.69
- CGEM N/A
- P/E Ratio
- WRLD $9.70
- CGEM N/A
- Revenue Growth
- WRLD N/A
- CGEM N/A
- 52 Week Low
- WRLD $101.85
- CGEM $8.92
- 52 Week High
- WRLD $161.63
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- WRLD 61.78
- CGEM 30.40
- Support Level
- WRLD $136.02
- CGEM $9.06
- Resistance Level
- WRLD $154.97
- CGEM $9.51
- Average True Range (ATR)
- WRLD 4.18
- CGEM 0.50
- MACD
- WRLD -0.66
- CGEM -0.05
- Stochastic Oscillator
- WRLD 54.30
- CGEM 6.18
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.